Crystalline forms of fused ring derivatives, methods for their preparation, and uses thereof

Crystalline forms of the fused ring derivative are produced through controlled crystallization, addressing purity and hygroscopicity issues, ensuring high purity and stability for industrial and clinical use.

JP2024545530AInactive Publication Date: 2024-12-09SHANGHAI YINGLI PHARMACEUTICAL CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024539651
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-04
Filing Date
2022-12-28
Publication Date
2024-12-09
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing production methods for the fused ring derivative 3-[4-(4-cyanophenyl)thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropionic acid result in low purity and high moisture absorption, leading to impurities exceeding internal control standards and hygroscopicity issues, which are detrimental to drug safety and efficacy.

Method used

The development of crystalline forms of the compound, characterized by specific X-ray diffraction peaks and low residual solvent content, is achieved through controlled crystallization processes using solvents like tetrahydrofuran and methanol, ensuring high purity and non-hygroscopicity.

Benefits of technology

The crystalline forms exhibit high purity, stability, and low moisture absorption, making them suitable for industrial production and clinical applications, with minimal residual solvent and effective impurity control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545530000001_ABST
    Figure 2024545530000001_ABST
Patent Text Reader

Abstract

The present invention discloses a crystalline form of a fused ring derivative, its preparation method and its use. The crystalline form I of the compound as represented by formula (A) of the present invention has high purity, good stability, non-hygroscopicity, and the crystallization solvent used in the preparation method has the advantages of low residual, which is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to Chinese patent application No. 202210000887.9, filed on January 4, 2022. The entire text of the above Chinese patent application is hereby incorporated by reference.

[0002] The present invention relates to the pharmaceutical field, specifically to a crystalline form of fused ring derivative 3-[4-(4-cyanophenyl)thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropionic acid, its preparation method and its use. [Background technology]

[0003] The fused ring derivative, 3-[4-(4-cyanophenyl)thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropionic acid, has the molecular formula C 19 H 16 N2O2S, whose structure is formula A

[0004] [ka]

[0005] (hereinafter referred to as the compound represented by formula A), which is a urate transporter 1 (URAT1) inhibitor that inhibits the reabsorption of uric acid in the proximal tubules of the kidney, thereby promoting the excretion of uric acid from the body via urinary fluid, and can effectively alleviate or treat hyperuricemia and related diseases.

[0006] It is well known that the phenomenon of crystal polymorphism of a substance is caused by two or more different arrangements of crystal structures. Different crystal forms of a compound often exhibit different physical and chemical properties. For drugs, different solid forms, including anhydrates, hydrates, solvates and amorphous, may have different physical and chemical properties such as melting point, hygroscopicity, solubility, dissolution rate, flowability, compressibility, stability, etc. to some extent. To ensure the safety, efficacy and quality consistency of drugs during clinical use, it is necessary to thoroughly study the phenomenon of crystal polymorphism of drugs in the drug research and development process and select the appropriate solid form for the clinical development of drugs.

[0007] Chinese invention patent CN106008340A discloses fused ring derivatives with obvious inhibitory effect on the activity of uric acid transporter hURAT1, including compound 48, which is a compound as shown in formula A of the present invention, and has IC 50 The total amount of the compound is 0.012 μmol, and it is expected that the compound can provide good clinical benefits to patients when administered at low doses. The compound as shown in formula A was prepared according to the preparation method of compound 48 disclosed in CN106008340A, and was confirmed to be amorphous by XRPD measurement. However, when the compound as shown in formula A is obtained by scaling up (e.g., the input amount is 27 g) using the above preparation method, the peak of an unknown impurity always exists at about 0.62 of the relative retention time (RRT) of the compound as shown in formula A in the collected reversed-phase high performance liquid chromatogram. Even if purification means such as slurrying and salt formation are used, it is difficult to completely remove the impurities or control them below the internal control standard (which should not exceed 0.10%), which affects the quality and safety of the drug product. Therefore, the product is purified by recrystallization to ensure that the purity of the drug meets the formulation and clinical needs.

[0008] It was also found that amorphous compounds such as those represented by formula A exhibit strong hygroscopicity under high humidity conditions, which is extremely disadvantageous for the storage of drugs and the development of solid preparations.

[0009] Therefore, there is an urgent need to produce compounds such as those represented by formula A in a solid form with low hygroscopicity, with strict control of the limits of unknown impurities to improve the purity of the final product and to meet the needs of final formulation and clinical application. Summary of the Invention [Problem to be solved by the invention]

[0010] The technical problem to be solved by the present invention is to address the shortcomings of low purity and severe hygroscopicity when the compound represented by formula A is produced on a large scale by the prior art process, and to provide a crystalline form of a fused ring derivative, a method for its preparation, and its use. The crystalline form of the present invention has the advantages of high purity, good stability, and non-hygroscopicity, and the crystallization solvent used in the preparation method has low residual, making it suitable for industrial production. [Means for solving the problem]

[0011] The present invention solves the above technical problems by the following technical solutions.

[0012] The present invention provides a crystalline form I of the compound as represented by formula A, having diffraction peaks at 8.3±0.2°, 12.8±0.2°, 13.4±0.2°, 17.5±0.2°, 17.9±0.2°, and 23.3±0.2° in terms of 2θ in an X-ray powder diffraction spectrum using Kα radiation of a Cu target.

[0013] The crystalline form I of the compound as represented by formula A further has diffraction peaks at 8.3±0.2°, 11.2±0.2°, 12.2±0.2°, 12.8±0.2°, 13.4±0.2°, 17.5±0.2°, 17.9±0.2°, 20.8±0.2°, 22.4±0.2°, and 23.3±0.2° in terms of 2θ in a powder X-ray diffraction spectrum using Kα radiation from a Cu target.

[0014] The crystalline form I of the compound as represented by formula A has diffraction peaks at 8.3±0.2°, 11.2±0.2°, 12.2±0.2°, 12.8±0.2°, 13.4±0.2°, 17.1±0.2°, 17.5±0.2°, 17.9±0.2°, 20.8±0.2°, 21.5±0.2°, 22.4±0.2°, 23.3±0.2°, 24.0±0.2°, 25.4±0.2°, 29.4±0.2°, and 34.5±0.2° in a powder X-ray diffraction spectrum using Kα radiation from a Cu target.

[0015] In some embodiments of the present invention, the crystalline form I of the compound as represented by formula A has a powder X-ray diffraction spectrum represented by the relative intensities of 2θ angle, d spacing, and peak height using Kα radiation of a Cu target, and the data of the relative intensities of 2θ angle, d spacing, and peak height of the diffraction peak can also be shown in Table 3.

[0016] [Table 3]

[0017] In some embodiments of the present invention, the crystalline form I of the compound as represented by formula A has the powder X-ray diffraction spectrum shown in FIG. 2 using Kα radiation of a Cu target.

[0018] In some embodiments of the present invention, the crystalline form I of the compound as represented by formula A has an infrared absorption spectrum (IR) of 3090 cm -1 , 3061cm -1 , 2965cm -1 , 2924cm -1 , 2868cm -1 , 2222cm -1 , 1697cm -1 , 1605cm -1 , 1578cm -1 , 1549cm -1 , 1499cm -1 , 1474cm -1 , 1420cm -1 , 1396cm -1 , 1296cm-1 , 1246cm -1 , 1188cm -1 , 1051cm -1 , and 920 cm -1 There is an absorption peak at

[0019] In some embodiments of the present invention, the infrared absorption spectrum of the crystalline form I of the compound as represented by formula A is shown in FIG.

[0020] In some embodiments of the present invention, the differential scanning calorimetry (DSC) chart of the crystalline form I of the compound as represented by formula A has an endothermic peak with an onset temperature of 193±2°C (e.g., 192.79°C) and a peak temperature of 195±2°C (e.g., 194.58°C).

[0021] In some embodiments of the present invention, the differential scanning calorimetry chart of crystalline form I of the compound of formula A is shown in FIG.

[0022] In some embodiments of the present invention, the thermogravimetric graph (TGA) of crystalline Form I of the compound of formula A shows no volatile loss when heated to 190°C.

[0023] In some embodiments of the present invention, the thermogravimetric graph of crystalline Form I of the compound of formula A is shown in FIG.

[0024] In some embodiments of the present invention, the dynamic moisture sorption (DVS) diagram of crystalline Form I of the compound as represented by formula A exhibits a weight increase of only about 0.01% within the relative humidity range of 0 to 95%.

[0025] In some embodiments of the present invention, the dynamic moisture sorption diagram of crystalline Form I of the compound as represented by formula A is shown in FIG.

[0026] In some embodiments of the present invention, the crystalline form I of the compound as represented by formula A has a liquid hydrogen nuclear magnetic spectrum ( 1 H NMR) 1The chemical shifts and integrals of the characteristic peaks in the H NMR spectrum were consistent with the structural formula of the compound represented by formula A, and it was confirmed that crystalline form I is the compound represented by formula A in an unsolvated solid form.

[0027] In one exemplary embodiment of the present invention, crystalline Form I of the compound as represented by formula A has a water content of 0.05% as determined by the Karl Fischer method, demonstrating that crystalline Form I is a pure anhydrous solid form.

[0028] The present invention also provides Method 1, which comprises cooling a mixture of a compound represented by formula A, THF and a poor solvent at 60-75°C, crystallizing, and filtering, wherein the poor solvent is methanol and / or water; or The present invention provides a method for producing crystalline form I of the compound represented by formula A, which comprises cooling a solution formed of crystalline form III and / or VI of the compound represented by formula A and a mixed solvent of THF and isopropyl alcohol at 60-70°C, precipitating a solid, and filtering the precipitated solid.

[0029] The compound as represented by formula A may be any form of the compound as represented by formula A, and may be obtained through any route; in some embodiments, the compound as represented by formula A is prepared according to patent CN106008340A.

[0030] In Scheme 1, the amount of THF used may be the amount commonly used in such operations in the art, as long as it can dissolve the compound as represented by Formula A, and in some embodiments, the volumetric mass ratio with the compound as represented by Formula A is 3.0-30.0 mL / g, for example, 4.0 mL / g, 7.0 mL / g, or 10.0 mL / g.

[0031] In method 1, the mixture is obtained by adding the compound represented by formula A to a mixed solvent of THF and a poor solvent, or by dissolving the compound represented by formula A in THF and then adding the poor solvent dropwise.

[0032] In some embodiments, the volume ratio of the THF to the anti-solvent is from 0.5:1 to 5:1.

[0033] In some embodiments, when the anti-solvent is methanol, the volume ratio of the THF to the anti-solvent is 0.5:1 to 2:1, for example, 1:1.

[0034] In some embodiments, when the anti-solvent is water, the volume ratio of the THF to the anti-solvent is from 0.5:1 to 5:1, for example, 1:1, 3.5:1, 4.4:1, or 5:1.

[0035] In Scheme 1, the cooling temperature is −20 to 20° C., for example, −8° C., 10° C. or 20° C. In Scheme 1, the cooling rate may be 5 to 30° C. / h, for example, 10° C. / h or 20° C. / h.

[0036] In method 1, the cooling further includes mixing the mixture with isopropyl alcohol and cooling the mixture, for example, cooling the mixture to 20 to -8°C, adding isopropyl alcohol, and then filtering the mixture.

[0037] In Scheme 1, the filtration can be a conventional procedure for such filtration in the art, such as vacuum suction filtration.

[0038] Method 1 may further include a drying operation after the filtration. The temperature and time of the drying may be generally determined by those skilled in the art. For example, in some embodiments, the drying may be performed under reduced pressure at 65° C., and the drying time may be 1 hour to 3 days.

[0039] In method 2, the temperature is decreased to a temperature of -20 to 20°C, for example, 5°C.

[0040] In method 2, the temperature drop rate is 5 to 30° C. / h, and may be, for example, 10° C. / h. o In Scheme 2, the volume ratio of THF to isopropyl alcohol in the mixed solvent is 0.5:1 to 2:1, and may be, for example, 1:1.

[0041] In method 2, the filtration can be a common procedure for such filtration in the art, such as vacuum suction filtration.

[0042] Method 2 may further include a drying operation after the filtration. The temperature and time of the drying may be generally determined by those skilled in the art. For example, in some embodiments, the drying may be performed under reduced pressure at 65° C., and the drying time may be 1 hour to 3 days.

[0043] In Scheme 2, the crystalline form III of the compound of Formula A is obtained by a preparation method comprising removing a solvent from a tetrahydrofuran solution of the compound of Formula A. The removal of the solvent may be carried out by distillation (e.g., vacuum distillation).

[0044] In Scheme 2, the preparation method of the crystalline form III of the compound of Formula A may further include filtering the tetrahydrofuran solution of the compound of Formula A before removing the solvent. The filtering may be a conventional filtering method in the art, such as filtering through a membrane filter, for example filtering through a 0.45 μm nylon membrane filter.

[0045] The crystalline form III of the compound as represented by formula A has diffraction peaks at 6.7±0.2°, 13.6±0.2°, 14.5±0.2°, 15.3±0.2°, 15.8±0.2°, 16.1±0.2°, 16.8±0.2°, 17.1±0.2°, 19.0±0.2°, 19.6±0.2°, 20.3±0.2°, and 22.6±0.2° in terms of 2θ in a powder X-ray diffraction spectrum using Kα radiation from a Cu target.

[0046] Furthermore, the crystalline form III of the compound represented by formula A may have a powder X-ray diffraction spectrum represented by the relative intensities of 2θ angle, d spacing, and peak height using Kα radiation of a Cu target, and the data of the relative intensities of 2θ angle, d spacing, and peak height of the diffraction peak may also be as shown in Table 4.

[0047] [Table 4]

[0048] The crystalline form III of the compound as represented by the formula A has a powder X-ray diffraction spectrum shown in FIG. 8 using Kα radiation of a Cu target.

[0049] The DSC chart of the crystalline form III of the compound represented by formula A is as shown in Figure 9. As shown in the DSC, the crystalline form III has an endothermic peak at an onset temperature of 103±2°C (e.g., 103.39°C) and a peak temperature of 111±2°C (e.g., 111.33°C), and an endothermic peak at an onset temperature of 192±2°C (e.g., 191.85°C) and a peak temperature of 193±2°C (e.g., 193.04°C).

[0050] The TGA chart of the crystalline form III of the compound represented by formula A is shown in Figure 10. As shown in the TGA, the crystalline form III loses 9.746% of its volatile weight when heated to about 190°C, and the weight loss above 190°C is due to decomposition.

[0051] In Scheme 2, the crystalline form VI of the compound as represented by formula A may be obtained by a preparation method including the steps of cooling a solution formed of the compound as represented by formula A and 1,4-dioxane to −10 to −20° C., filtering and drying.

[0052] In Scheme 2, in the preparation method of the crystalline form VI of the compound represented by formula A, the temperature of the solution formed by the compound represented by formula A and 1,4-dioxane is 40-120°C, for example, 105±5°C.

[0053] In Scheme 2, in the preparation method of crystalline form VI of the compound represented by formula A, the cooling is rapid cooling, for example, immediately placing in a refrigerator at -10 to -20°C, and the time for the standing may be 1 to 3 days, for example, 3 days.

[0054] In Scheme 2, in the preparation method of the crystalline form VI of the compound as represented by formula A, the filtration can be a common operation for such filtration in the art, such as vacuum suction filtration.

[0055] In Scheme 2, in the preparation method of crystalline form VI of the compound as represented by formula A, the drying may be vacuum drying, for example, 60°C vacuum drying.

[0056] The crystalline form VI of the compound as represented by formula A has diffraction peaks at 6.3±0.2°, 12.7±0.2°, 14.1±0.2°, 14.6±0.2°, 17.3±0.2°, 17.8±0.2°, 19.1±0.2°, 19.5±0.2°, 22.4±0.2°, 24.6±0.2°, and 25.2±0.2° in terms of 2θ in a powder X-ray diffraction spectrum using Kα radiation from a Cu target.

[0057] Furthermore, the crystalline form VI of the compound as represented by formula A may have a powder X-ray diffraction spectrum represented by the relative intensities of 2θ angle, d spacing, and peak height using Kα radiation of a Cu target, and the data of the relative intensities of 2θ angle, d spacing, and peak height of the diffraction peak may also be as shown in Table 5.

[0058] [Table 5]

[0059] The crystalline form VI of the compound as represented by the formula A has a powder X-ray diffraction spectrum shown in FIG. 12 using Kα radiation of a Cu target.

[0060] The DSC chart of the crystalline form VI of the compound represented by formula A is shown in Figure 13. As shown in the DSC, the crystalline form VI has an endothermic peak at an onset temperature of 140±2°C (e.g., 140.47°C) and a peak temperature of 146±2°C (e.g., 145.60°C), and an endothermic peak at an onset temperature of 192±2°C (e.g., 191.92°C) and a peak temperature of 193±2°C (e.g., 193.21°C).

[0061] The TGA chart of the crystalline form VI of the compound represented by formula A is shown in Figure 14. As shown in the TGA, the crystalline form VI loses 11.545% of its volatile weight when heated to about 190°C, and the weight loss above 190°C is due to decomposition.

[0062] The present invention also provides a crystalline form IV of the compound as represented by formula A, having diffraction peaks at 8.4±0.2°, 12.8±0.2°, 13.5±0.2°, 16.1±0.2°, 16.7±0.2°, 16.9±0.2°, 17.6±0.2°, 17.9±0.2°, 18.9±0.2°, 22.7±0.2°, 23.4±0.2°, 24.1±0.2°, and 25.5±0.2° in terms of 2θ in an X-ray powder diffraction spectrum using Kα radiation from a Cu target.

[0063] Furthermore, the crystalline form IV of the compound represented by formula A may have a powder X-ray diffraction spectrum represented by the relative intensities of 2θ angle, d spacing, and peak height using Kα radiation of a Cu target, and the data of the relative intensities of 2θ angle, d spacing, and peak height of the diffraction peak may also be as shown in Table 6.

[0064] [Table 6]

[0065] The crystalline form IV of the compound as represented by the formula A has a powder X-ray diffraction spectrum shown in FIG. 16 using Kα radiation of a Cu target.

[0066] The DSC chart of the crystalline form IV of the compound represented by formula A is shown in Figure 17. As shown in the DSC, the crystalline form IV has an endothermic peak at an onset temperature of 191±2°C (e.g., 191.36°C) and a peak temperature of 194±2°C (e.g., 193.60°C).

[0067] The TGA chart of the crystalline form IV of the compound represented by formula A is shown in Figure 18. As shown in the TGA, the crystalline form IV loses 0.364% of volatile matter by weight when heated to about 190°C, and the weight loss above 190°C is due to decomposition.

[0068] The water content of the crystalline form IV of the compound as represented by formula A was determined to be 0.3% by Karl Fischer method, which demonstrated that the crystalline form IV was a pure anhydrous solid form.

[0069] The crystalline form IV of the compound represented by formula A can be obtained by a preparation method including the steps of cooling a solution formed of the compound represented by formula A and 1,4-dioxane to room temperature, crystallizing, filtering and drying the solution.

[0070] In some embodiments, the temperature of the solution formed from the compound represented by formula A and 1,4-dioxane is 40 to 120°C, for example, 80°C.

[0071] The solution may be a saturated solution, which may be filtered, for example a saturated solution filtered while hot through a 0.45 μm nylon filter membrane.

[0072] In some embodiments, the temperature decrease may be a slow decrease, and the rate of the decrease may be 5° C. / h.

[0073] In some embodiments, the crystallization temperature is room temperature.

[0074] The filtration may be a common procedure for such filtration in the art, for example, vacuum suction filtration.

[0075] The drying may be vacuum drying, for example, vacuum drying at 40°C.

[0076] The present invention provides the use of crystalline form I of the compound as represented by formula A in the manufacture of a medicament for preventing and / or treating hyperuricemia or diseases related thereto.

[0077] The diseases associated with hyperuricemia are, for example, one or more of gout, hypertension, diabetes, hypertriglyceridemia, metabolic syndrome, coronary heart disease, and kidney damage.

[0078] The present invention provides a method for preventing and / or treating hyperuricemia or a disease associated therewith, comprising administering to a subject an effective amount of crystalline Form I of the compound as represented by formula A. The disease associated with hyperuricemia is, for example, one or more of gout, hypertension, diabetes, hypertriglyceridemia, metabolic syndrome, coronary heart disease, and kidney damage.

[0079] The present invention also provides the use of crystalline form I of the compound as represented by formula A in the manufacture of a urate transporter 1 inhibitor.

[0080] The present invention also provides a method of inhibiting urate transporter 1, comprising administering to a subject an effective amount of crystalline form I of a compound as represented by formula A above.

[0081] In some embodiments of the invention, the urate transporter 1 inhibitors may be used in vivo in a mammal or may be used in vitro primarily for experimental purposes, e.g., provided for comparison as a standard or control sample, or prepared into a kit for rapid detection of urate transporter 1 inhibitory effects by methods routine in the art.

[0082] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of crystalline Form I of the compound as represented by formula A above, and one or more pharma- ceutically acceptable carriers and / or diluents.

[0083] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form I of the compound as represented by formula A above and another uric acid lowering agent.

[0084] The other uric acid lowering agent is one or more of a urate transporter 1 inhibitor, a xanthine oxidase inhibitor, a xanthine oxidoreductase, and a xanthine dehydrogenase inhibitor.

[0085] In some embodiments of the invention, the other uric acid lowering agent is allopurinol and / or febuxostat.

[0086] In the present invention, the method of administration of the pharmaceutical composition is not particularly limited, and various dosage forms of preparations can be selected and administered according to the age, sex, other conditions and symptoms of the patient. For example, tablets, pills, solutions, suspensions, emulsions, granules, or capsules are administered orally, injections can be administered alone or mixed with an injection transport solution (such as a glucose solution or an amino acid solution) and administered intravenously, and suppositories are administered rectally.

[0087] In some instances, the crystalline form I of the compound as represented by formula A does not convert when formulated with one or more pharma- ceutically acceptable carriers and / or auxiliary materials and / or diluents.

[0088] In some instances, the crystalline form I of the compound as represented by formula A above does not convert when forming a pharmaceutical composition with other uric acid lowering agents.

[0089] Based on the common knowledge in the art, each of the above preferred conditions can be arbitrarily combined to obtain each of the preferred embodiments of the present invention.

[0090] In the present invention, compound 48-a is synthesized with reference to CN106008340A, and other reagents and raw materials used are all commercially available.

[0091] In the present invention, unless otherwise specified, the ratio of solvents is a volume ratio.

[0092] The positive effects of the present invention are as follows: The crystalline form I of the compound as represented by formula A according to the present invention has high purity, meets the needs of pharmaceutical preparation and clinical application, has good stability, is non-hygroscopic, is not prone to crystal transition, is simple to prepare, has little residual crystallization solvent used, and is suitable for industrial production. [Brief description of the drawings]

[0093] [Figure 1] FIG. 1 is a powder X-ray diffraction spectrum diagram of the amorphous compound as shown in formula A obtained in Example 1 according to the method of patent CN106008340A. [Diagram 2] FIG. 2 is a powder X-ray diffraction spectrum of crystalline form I of the compound of formula A. [Diagram 3] FIG. 2 is an infrared absorption spectrum of crystalline form I of the compound of formula A. [Figure 4] 1 is a differential scanning calorimetry chart of crystalline form I of the compound of formula A. [Diagram 5] 1 is a thermogravimetric graph of crystalline form I of the compound as shown in formula A. [Figure 6] FIG. 2 is a dynamic moisture sorption diagram of crystalline form I of the compound as shown in formula A, where 1 is the moisture absorption curve and 2 is the moisture desorption curve. [Figure 7]FIG. 2 is a liquid hydrogen nuclear magnetic spectrum of the crystalline form I of the compound represented by formula A. [Figure 8] FIG. 2 is a powder X-ray diffraction spectrum of crystalline form III of the compound as represented by formula A. [Figure 9] 1 is a differential scanning calorimetry chart of crystalline form III of the compound of formula A. [Figure 10] 1 is a thermogravimetric graph of crystalline Form III of the compound as shown in formula A. [Figure 11] FIG. 2 is a liquid hydrogen nuclear magnetic spectrum of the crystalline form III of the compound represented by formula A. [Figure 12] FIG. 2 is a powder X-ray diffraction spectrum of crystalline form VI of the compound as represented by formula A. [Figure 13] 1 is a differential scanning calorimetry chart of crystalline form VI of the compound of formula A. [Figure 14] 1 is a thermogravimetric graph of crystalline Form VI of the compound as shown in formula A. [Figure 15] FIG. 2 is a liquid hydrogen nuclear magnetic spectrum of the crystalline form VI of the compound represented by formula A. [Figure 16] FIG. 2 is a powder X-ray diffraction spectrum of crystalline form IV of the compound of formula A. [Figure 17] 1 is a differential scanning calorimetry chart of crystalline form IV of the compound of formula A. [Figure 18] 1 is a thermogravimetric graph of crystalline Form IV of the compound as shown in formula A. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0094] The present invention will be further described below using examples, but the present invention is not limited to the scope of the described examples. In the following examples, the experimental methods for which specific conditions are not specified are selected according to conventional methods and conditions or according to product instructions. The solvents in the following examples are all analytical purity or chromatographic purity. When the solvents in the following examples are mixed solvents, the ratios are by volume unless otherwise specified.

[0095] Test equipment and test conditions used in the present experiment (1) X-ray Powder Diffraction Spectrum (XRPD: X-Ray Powder Diffraction) For detection, a Bruker D8 Advance type powder X-ray diffractometer was used, using Cu-Kα radiation (λ = 1.5406 A). The voltage was 40 kV, the current was 40 mA, the step length was 0.02°, the scan speed was 8° / min, and the scan range was 4 to 40°.

[0096] (2) Infrared Absortion Spectroscopy (IR) For detection, a Shimadzu Presitage 21-type Fourier transform infrared spectrometer was used, and the test sample was prepared by the potassium bromide tableting method in accordance with the Chinese Pharmacopoeia 2020, Part 4, General Provisions 0402 Infrared Spectroscopy Method. -1 The infrared absorption spectrum is collected within the wave number range of 45 scans of the test sample, and the resolution of the instrument is 4 cm. -1 It is.

[0097] (3) Differential Scanning Calorimetry (DSC) For detection, a Q2000 or DSC25 type differential scanning calorimeter manufactured by TA Instruments is used, the atmosphere is nitrogen, the heating rate is 10°C / min, and the temperature range is 25 to 300°C.

[0098] (4) Thermo Gravimetric Analysis (TGA) For detection, a TA Instrument Q500 thermogravimetric analyzer is used, the atmosphere is nitrogen, the heating rate is 10°C / min, and the heating range is 25 to 300°C.

[0099] (5) Dynamic Vapor Sorption (DVS) For detection, SMS Advantage 1.0 type dynamic moisture adsorption device is used. The temperature is 25℃, the relative humidity range is 0-95%, and the humidity change step is 5% relative humidity. When the value of the mass change rate dm / dt is less than 0.002%, the balance is considered to be equilibrated. When the mass change rate within 5 minutes is less than 0.01% / min, it is the equilibration criterion for the detection process, and the maximum equilibration time is 2 hours.

[0100] (6) Liquid hydrogen nuclear magnetic spectrum ( 1 H NMR:Proton Nuclear Magnetic Resonance) Liquid hydrogen nuclear magnetic spectra were collected on a Bruker 400 MHz nuclear magnetic resonance spectrometer and the samples were dissolved in dimethylsulfoxide-d6.

[0101] Example 1 Synthesis of a compound as represented by formula A The synthesis scheme for the compound of formula A is as follows.

[0102] [ka]

[0103] According to the synthesis method of compound 48 in Chinese invention patent CN106008340A, 27 g of compound 48-a (3-[4-(4-cyanophenyl)thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropionate methyl) (76 mmol) was added to a mixed solution of methanol (200 mL), tetrahydrofuran (1.0 L) and water (200 mL) at room temperature, and 13 g of lithium hydroxide (308 mmol) was further taken and added to the mixture. The mixture was stirred for 6 hours, adjusted to pH=5-6 by adding 1M aqueous hydrochloric acid solution, and concentrated under reduced pressure. The residue was adjusted to pH=7-8 with 2M aqueous sodium hydroxide solution, and extracted with ethyl acetate (2 L) to remove impurities. The aqueous phase was adjusted to pH=5-6 with 1M aqueous hydrochloric acid solution, and extracted with ethyl acetate (3 L x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered by vacuum suction. The filtrate was distilled under reduced pressure to give 20 g of a yellow solid.

[0104] LC-MS(ESI): m / z=337[M+H] + .

[0105] 1 H NMR (400MHz, DMSO- d6 )δ12.58(s,1H),9.21(s,1H),8.49(s,1H),8.03(d,2H,J=8.4Hz),7.84(d,2H,J=8.4Hz),7.30(s,1H),3.22(s,2H),1.17(s,6H).

[0106] 1 The H NMR and LC-MS (ESI) measurements confirmed that the resulting yellow solid was compound 48, i.e., the compound as shown in formula A of the present invention. A suitable amount of sample was taken and tested for XRPD, which showed that it was amorphous, and the XRPD spectrum diagram is shown in FIG.

[0107] The final sample concentration was 1 mg / mL in acetonitrile / water / trifluoroacetic acid (300 / 700 / 2). Reverse-phase HPLC analysis was performed using a Waters SunFire column (3.5 μm, 4.6 × 150 mm). Chromatographic conditions: 0.1% trifluoroacetic acid-water solution was mobile phase A, 0.1% trifluoroacetic acid-acetonitrile solution was mobile phase B, and mobile phase B was increased from 15% to 23% within 14 min, then increased from 23% to 32% within 16 min, further increased from 32% to 80% within 15 min and maintained for 5 min, and finally restored from 80% to 15% within 0.01 min and maintained for 10 min. The column temperature was 30 °C, the sample injection volume was 10 μL, and the detection wavelength was 246 nm. The purity of the compound represented by formula A in the sample was measured by the area normalization method to be 98.6%, and the content of unknown impurities at the retention time (RRT) of the compound represented by formula A of about 0.62 in the high performance liquid chromatogram was 0.17%, which exceeded the internal control standard (must not exceed 0.10%). The compound represented by formula A produced in Example 1 was used as the starting material in the following Examples 2 to 8.

[0108] Example 2 Extractive purification of the compound as represented by formula A According to the following procedures, the compounds as shown in formula A were purified, and the experimental results are shown in Table 1 below.

[0109] Three 0.5 g portions of the compound represented by formula A were taken, each containing 5 mL of water, and adjusted to pH=11 with 10% sodium carbonate solution or 2M lithium hydroxide solution to dissolve all solids, then extracted with 2-methyltetrahydrofuran, dichloromethane, or toluene (5 mL×2), respectively, to remove impurities. The aqueous phase was adjusted to pH=3-4 with 1M aqueous hydrochloric acid, filtered, and dried.

[0110] The purity of the product was analyzed by reverse phase HPLC and the crystalline form of the product was determined by XRPD.

[0111] [Table 1]

[0112] From the above results, it was found that although extraction with an organic solvent has a certain effect on removing unknown impurities at an RRT of approximately 0.62, it is not possible to strictly control the impurities below the internal control standard (which must not exceed 0.10%).

[0113] Example 3 Purification of a compound as represented by formula A by slurrying The purification effect of slurrying with different solvents on the compound as represented by formula A was investigated according to the following procedure. The experimental results are shown in Table 2 below.

[0114] Three 0.1 g portions of the compound as represented by formula A were each added with an appropriate volume of a single solvent or a mixture of solvents, slurried at room temperature for 4 hours, filtered and dried.

[0115] The purity of the product was analyzed by reverse phase HPLC and the crystalline form of the product was determined by XRPD.

[0116] [Table 2]

[0117] From the above results, it was found that the unknown impurities at RRT of about 0.62 could not be controlled to below the internal control standard (must not exceed 0.10%) by the slurry.

[0118] Example 4 Preparation of Crystalline Form I of Compound as Represented by Formula A 5.0 g of the compound represented by formula A was refluxed at 70-75°C in a mixed solvent of 35 mL of tetrahydrofuran and 7 mL of water, and stirred to obtain a hot clear solution, and the temperature was slowly lowered to about 10°C at a rate of 10°C / hour, and the precipitated solid was filtered and dried overnight at 65°C under reduced pressure to obtain 2.2 g of a white solid in a yield of 44.5%. When the compound represented by formula A in this solid was analyzed by reverse phase HPLC, the purity was 99.6%, and the content of unknown impurities at RRT about 0.62 was 0.05%.

[0119] The obtained solid is crystalline form I of the compound represented by formula A, and its powder X-ray diffraction spectrum is as shown in Figure 2. For this solid, the data of the 2θ angle of the main diffraction peak, d spacing, and relative intensity of peak height expressed in 2θ angle in the powder X-ray diffraction spectrum are shown in Table 3 below.

[0120] [Table 3]

[0121] The IR diagram of the crystalline form I is shown in FIG. -1 , 3061cm -1 , 2965cm -1 , 2924cm -1 , 2868cm -1 , 2222cm -1 , 1697cm -1 , 1605cm -1 , 1578cm -1 , 1549cm -1, 1499cm -1 , 1474cm -1 , 1420cm -1 , 1396cm -1 , 1296cm -1 , 1246cm -1 , 1188cm -1 , 1051cm -1 , and 920 cm -1 There is an absorption peak at

[0122] The DSC chart of the crystalline form I is shown in FIG. 4, and the endothermic peak had an onset temperature of 192.79°C and a peak temperature of 194.58°C.

[0123] TGA showed that the Form I lost only 0.054% weight of volatile matter when heated to 190° C. The weight loss above 190° C. was due to decomposition. The TGA chart is shown in FIG.

[0124] DVS showed that the crystalline form I had only a 0.00944% weight increase from RH 0% to RH 95%, as shown in FIG.

[0125] 1 The chemical shifts and integrals of the characteristic peaks of the crystalline form I obtained by H NMR test are consistent with the structural formula of the compound as shown in formula A, and no characteristic peaks of residual crystallization solvent were observed. 1 The 1 H NMR spectrum is shown in FIG.

[0126] The water content of Form I was determined to be 0.05% by Karl Fischer method, demonstrating that Form I is an anhydrous solid form of the compound as represented by formula A.

[0127] Residual Solvents Measurement Method (Chinese Pharmacopoeia 2020 Edition) <0861> According to gas chromatography (GC) analysis according to the method of claim 1, the residual solvents in said crystalline form I meet the prescribed limit (tetrahydrofuran must not exceed 0.072%).

[0128] Example 5 Preparation of Crystalline Form I of Compound as Represented by Formula A 0.3 g of the compound as shown in formula A was refluxed at about 60°C in a mixed solvent of 1.2 mL of tetrahydrofuran and 1.2 mL of methanol, and stirred to obtain a hot clear solution. The temperature was slowly lowered to about 20°C at a rate of 10°C / h, and the precipitated solid was filtered and dried overnight at 65°C under reduced pressure to obtain 0.21 g of a white solid with a yield of 70.0%. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystalline form I. The compound as shown in formula A in this sample was analyzed by reverse phase HPLC, and its purity was 99.5%, and the content of unknown impurities at RRT about 0.62 was 0.09%. Residual Solvent Determination Method (Chinese Pharmacopoeia 2020 Edition) <0861> ) the residual solvents in this sample meet the prescribed limits (tetrahydrofuran must not exceed 0.072% and methanol must not exceed 0.3%).

[0129] Example 6 Preparation of Crystalline Form I of Compound as Represented by Formula A 0.5 g of the compound as shown in formula A was mixed with 5 mL of tetrahydrofuran / water (7 / 1.6, V / V) at 65±5°C, stirred for 24 hours while keeping warm, cooled to about 10°C at a rate of 30°C / h, and the precipitated solid was filtered and dried overnight at 65°C under reduced pressure to obtain 0.37 g of a white solid with a yield of 74.0%. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystalline form I. The compound as shown in formula A in this sample was analyzed by reverse phase HPLC, and its purity was 99.8%, and the content of unknown impurities at RRT about 0.62 was 0.02%. Residual Solvent Determination Method (Chinese Pharmacopoeia 2020 Edition) <0861> ) the residual solvents in this sample meet the prescribed limit (tetrahydrofuran must not exceed 0.072%).

[0130] Example 7 Preparation of Crystalline Form I of Compound as Represented by Formula A 1.0 g of the compound as shown in formula A was refluxed in 10 mL of tetrahydrofuran at 65-70 ° C, stirred to obtain a hot clear liquid, slowly dripped with 10 mL of water, slowly lowered the temperature to about 10 ° C at a rate of 10 ° C / h, stirred overnight while keeping warm, filtered off the precipitated solid, dried overnight at 65 ° C under reduced pressure, and obtained 0.65 g of a white solid with a yield of 65.0%. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystalline form I. The compound as shown in formula A in this sample was analyzed by reverse phase HPLC, and its purity was 99.8%, and the content of unknown impurities at RRT about 0.62 was 0.02%. Residual Solvent Determination Method (Chinese Pharmacopoeia 2020 Edition <0861> ) the residual solvents in this sample meet the prescribed limit (tetrahydrofuran must not exceed 0.072%).

[0131] Example 8 Preparation of Crystalline Form I of Compound as Represented by Formula A 1.0 g of the compound as shown in formula A was refluxed at 70-75 ° C in a mixed solvent of 7 mL of tetrahydrofuran and 2 mL of water, and stirred to obtain a hot clear liquid, and the temperature was slowly lowered to about 20 ° C at a rate of 10 ° C / h, 5 mL of isopropyl alcohol was added, the temperature was slowly lowered to about -8 ° C at a rate of 10 ° C / h, and stirred for 5 hours, and the precipitated solid was filtered and dried under reduced pressure at 65 ° C overnight to obtain 0.76 g of a white solid with a yield of 76.0%. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystalline form I. The compound as shown in formula A in this sample was analyzed by reverse phase HPLC, and its purity was 99.9%, and the content of unknown impurities at RRT about 0.62 was 0.02%. Residual Solvent Determination Method (Chinese Pharmacopoeia 2020 Edition <0861> ) the sample contained no residual tetrahydrofuran and contained 0.18% isopropanol, thus meeting the prescribed limits for residual solvents (tetrahydrofuran must not exceed 0.072% and isopropyl alcohol must not exceed 0.5%).

[0132] Example 9 Preparation of Crystalline Form I of Compound as Represented by Formula A 0.1 g of the compound as shown in formula A (crystal form III) was mixed with a mixed solvent of 0.5 mL of tetrahydrofuran and 0.5 mL of isopropanol, and stirred at 60-70°C to obtain a hot clear liquid, and the temperature was slowly lowered to about 5°C at a rate of 10°C / hour, and the precipitated solid was filtered and dried overnight at 65°C under reduced pressure. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystal form I.

[0133] When the compound represented by formula A in this sample was analyzed by reverse phase HPLC, its purity was 99.8% and the content of unknown impurities at RRT about 0.62 was 0.07%.

[0134] Example 10 Preparation of Crystalline Form I of Compound as Represented by Formula A 0.1 g of the compound as shown in formula A (crystalline form VI) was mixed with 0.5 mL of tetrahydrofuran and 0.5 mL of isopropanol, and stirred at 60-70°C to obtain a hot clear liquid, and the temperature was slowly lowered to about 5°C at a rate of 10°C / hour, and the precipitated solid was filtered and dried overnight at 65°C under reduced pressure. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystalline form I.

[0135] When the compound represented by formula A in this sample was analyzed by reverse phase HPLC, its purity was 99.8% and the content of unknown impurities at RRT about 0.62 was 0.05%.

[0136] Example 11 Preparation of Crystalline Form I of Compound as Represented by Formula A A crude product of the compound represented by formula A was synthesized again in one batch according to the method of Example 1. The compound represented by formula A in this crude product was analyzed by reverse phase HPLC, and its purity was 99.1%, and the content of unknown impurities at RRT about 0.62 was 0.15%. 50 g of this crude product was taken, refluxed at 70-75 ° C in a mixed solvent of 350 mL of tetrahydrofuran and 100 mL of water, and stirred to obtain a hot clear liquid, and the temperature was slowly lowered to about 20 ° C at a rate of 10 ° C / h, 250 mL of isopropyl alcohol was added, and the temperature was slowly lowered to about -8 ° C at a rate of 10 ° C / h, and stirred for 5 hours, and the precipitated solid was filtered and dried overnight at 65 ° C under reduced pressure, and 41.0 g of white solid was obtained in a yield of 82.0%. The powder X-ray diffraction spectrum of this sample was examined and compared, and it was found to be crystalline form I. The compound represented by formula A in this sample was analyzed by reverse phase HPLC, and its purity was 99.9%. The content of unknown impurities at RRT of about 0.62 was 0.01%. Residual Solvents Determination Method (Chinese Pharmacopoeia 2020 Edition) <0861> ) Analysis by GC in this sample showed that there was no residual tetrahydrofuran and the isopropanol content was 0.073%, meeting the prescribed limits for residual solvents (tetrahydrofuran must not exceed 0.072% and isopropyl alcohol must not exceed 0.5%).

[0137] Example 12 Preparation of Crystalline Form III of Compound as Represented by Formula A Take 0.75g of the crude product of the compound represented by formula A prepared in Example 11, mix with 50mL of tetrahydrofuran at room temperature, and ultrasonically treat until the solid is clearly dissolved. Then, filter through a 0.45μm nylon filter membrane. The filtrate is distilled under reduced pressure at room temperature to remove the solvent, and obtain 0.70g of a white solid with a yield of 93.2%.

[0138] The obtained solid is crystalline form III of the compound represented by formula A, and its powder X-ray diffraction spectrum is shown in Figure 8. The data of the 2θ angle of the main diffraction peak, d spacing, and relative intensity of peak height in the powder X-ray diffraction spectrum of this solid are shown in Table 4 below.

[0139] [Table 4]

[0140] DSC showed that the crystalline form III had an endothermic peak at an onset temperature of 103.39° C. and a peak temperature of 111.33° C., and an endothermic peak at an onset temperature of 191.85° C. and a peak temperature of 193.04° C. The DSC chart is shown in FIG.

[0141] TGA showed that the crystalline form III lost 9.746% weight of volatiles when heated to about 190° C., and the weight loss above 190° C. was due to decomposition. The TGA chart is shown in FIG.

[0142] The crystalline form III 1 The H NMR spectrum is shown in Figure 11. 1Comparing with the H NMR spectrum (Figure 7), a peak with an integral value of 1.97 appears at a chemical shift of 1.76 ppm, and the shift indicates that this peak is a characteristic peak of the four hydrogen atoms of the methylene group (-CH2-) of tetrahydrofuran. A peak with an integral value of 1.97 appears at 3.60 ppm, and the shift indicates that this peak is a characteristic peak of the four hydrogen atoms of the methyleneoxy group (-CHO-) of tetrahydrofuran. It is known that the six hydrogen atoms of the two methyl groups (-CH3) of the compound represented by formula A have a peak at 1.17 ppm with an integral value of 6.00, so it was estimated that about 0.5 moles of tetrahydrofuran are bound to the crystal form III.

[0143] The compound of formula A in said crystalline form III was analyzed by reverse phase HPLC to find that its purity was 99.1% and the content of unknown impurity was 0.15% at RRT about 0.62.

[0144] Example 13 Preparation of Crystalline Form VI of Compound as Represented by Formula A Take 1.0 g of the crude product of the compound represented by formula A prepared in Example 11, reflux it in 10 mL of 1,4-dioxane at 105±5°C, stir to obtain a hot clear liquid, which is then placed in a refrigerator at -20°C for 3 days and then taken out. The solid is filtered at room temperature and dried under reduced pressure at 60°C for 2 hours to obtain 0.65 g of a white solid with a yield of 65.3%.

[0145] The obtained solid is crystalline form VI of the compound represented by formula A, and its powder X-ray diffraction spectrum is shown in Figure 12. The data of the main diffraction peak 2θ angle, d spacing, and relative intensity of peak height expressed in 2θ angle in the powder X-ray diffraction spectrum of this solid are shown in Table 5 below.

[0146] [Table 5]

[0147] DSC showed that the crystalline form VI had an endothermic peak at an onset temperature of 140.47° C. and a peak temperature of 145.60° C., and an endothermic peak at an onset temperature of 191.92° C. and a peak temperature of 193.21° C. The DSC chart is shown in FIG.

[0148] TGA showed that the crystalline form VI lost 11.545% of its volatile weight when heated to about 190° C., and the weight loss above 190° C. was due to decomposition. The TGA chart is shown in FIG.

[0149] The crystalline form VI 1 The H NMR spectrum is shown in Figure 15. 1 Comparing with the H NMR spectrum (FIG. 7), a peak with an integral value of 3.79 appears at a chemical shift of 3.57 ppm, and it is found from the shift that this peak is a characteristic peak of a total of eight hydrogens of four methylene groups (-CH2-) of 1,4-dioxane. It is known that the six hydrogens of two methyl groups (-CH3) of a compound as shown in formula A have a peak at 1.17 ppm with an integral value of 6.00, so it was estimated that about 0.5 moles of 1,4-dioxane is bound to the crystal form VI.

[0150] The compound of formula A in said crystalline form VI was analyzed by reverse phase HPLC to have a purity of 99.6% and a content of unknown impurity of 0.13% at RRT about 0.62.

[0151] Example 14 Preparation of Crystalline Form IV of the Compound as Represented by Formula A 1.0 g of the crude product of the compound represented by formula A prepared in Example 11 was added to 20 mL of 1,4-dioxane and stirred at about 80° C. until it was dissolved and almost clear. While still hot, the mixture was quickly filtered through a 0.45 μm nylon filter membrane. The filtrate was cooled slowly to room temperature at a rate of 5° C. / hour. The solid was filtered off and dried overnight at 40° C. under reduced pressure to obtain 0.50 g of a white solid with a yield of 50.0%.

[0152] The obtained solid is crystalline form IV of the compound represented by formula A, and its powder X-ray diffraction spectrum is shown in Figure 16. The data of the relative intensity of the main diffraction peak 2θ angle, d spacing and peak height expressed in 2θ angle in the powder X-ray diffraction spectrum of this solid are shown in Table 6 below.

[0153] [Table 6]

[0154] DSC showed that the crystalline form IV had an endothermic peak at an onset temperature of 191.36° C. and a peak temperature of 193.60° C. The DSC chart is shown in FIG.

[0155] TGA showed that the crystalline form IV lost 0.364% weight of volatile matter when heated to about 190° C., and the weight loss above 190° C. was due to decomposition. The TGA chart is shown in FIG.

[0156] Residual Solvents Measurement Method (Chinese Pharmacopoeia 2020 Edition) <0861> ) and analyzed by GC, the 1,4-dioxane residues in said crystalline form IV meet the prescribed limit (must not exceed 0.038%).

[0157] The water content of Form IV was determined to be 0.3% by Karl Fischer method, demonstrating that Form IV is another anhydrous solid form of the compound as shown in formula A.

[0158] The compound of formula A in said crystalline form IV was analyzed by reverse phase HPLC to find that its purity was 99.7% and the content of unknown impurity at RRT about 0.62 was 0.12%.

[0159] Example 15 Heating Experiment Approximately 50 mg of each of the crystal forms I, III, VI, and IV samples of the compound of formula A obtained in Examples 11, 12, 13, and 14 were taken and spread flat on a clean glass dish, respectively, and heated in a constant temperature oven at 105° C. for about 1 hour, and immediately after removal, the XRPD was tested.

[0160] Conclusion: For the crystalline form I and the crystalline form IV, the XRPD of the samples heated at 105°C did not change compared to those before heating. For the crystalline form III and the crystalline form VI, by comparison, the XRPD spectrum of the samples heated at 105°C was consistent with the XRPD spectrum of the crystalline form I of the compound as represented by formula A according to the present invention. After the solvent was removed by heating, the crystalline form III and the crystalline form VI were transformed into the crystalline form I of the compound as represented by formula A according to the present invention, and it was proved that the crystalline form III and the crystalline form VI were not as thermally stable as the crystalline form I.

[0161] Example 16 Stability 1. Stability of Form I and Form IV of the compound represented by formula A in solvents 1.1 Stability experiment of crystalline form I of the compound as represented by formula A in solvents at room temperature Approximately 30 mg of crystalline form I of the compound as represented by formula A was mixed in 1 mL of solvent, sonicated to form a slurry, and equilibrated in suspension at room temperature for a period of time (7 days or 14 days), ensuring that there was always an excess of solid in the bottle during this period, centrifuged to collect the solid, evaporated the solvent at room temperature, and tested for XRPD.

[0162] Conclusion: In the present invention, the crystalline form I has good stability in various single or mixed solvents at room temperature, for example, after equilibration by suspension in methanol, ethanol, isopropyl alcohol, n-butanol, acetone, 2-butanone, methyl isobutyl ketone, dichloromethane, 2-methyltetrahydrofuran, acetonitrile, n-heptane, n-hexane, cyclohexane, cyclopentane, n-pentane, isopropyl ether, methyl tert-butyl ether, ethyl acetate, or isopropyl acetate at room temperature for 7 days, the crystalline form can be kept unchanged in all of them. After equilibration by suspension at room temperature for 14 days in water, a mixture of methanol and water (volume ratios of 90:10, 75:25, 45:55, and 10:90, respectively), a mixture of ethanol and water (volume ratios of 95:5, 90:10, 65:35, and 15:85, respectively), a mixture of isopropyl alcohol and water (volume ratios of 95:5, 85:15, and 15:85, respectively), and a mixture of acetone and water (volume ratios of 95:5, 85:15, and 15:85, respectively), the crystal form can be maintained unchanged in all of them.

[0163] 1.2 Stability experiment of crystalline form I of the compound of formula A in solvent at high temperature About 50 mg of crystalline form I of the compound as represented by formula A was mixed in 1 mL of solvent, ultrasonically dispersed to form a slurry, and equilibrated by shaking on a thermostatic shaking table at 50° C. During this period, it was ensured that there was always an excess of solid in the bottle, and after equilibration for a certain period of time, the slurry was centrifuged to collect the solid, the solvent was evaporated at room temperature, and XRPD was tested.

[0164] Conclusion: In the present invention, the crystalline form I has good stability in various single or mixed solvents at 50°C. For example, after equilibration in methanol, ethanol, isopropyl alcohol, acetone, or ethyl acetate for 43 days, the crystalline form can be kept unchanged in all of them. After equilibration in a 50:50 volume ratio mixture of methanol and water, a mixture of ethanol and water, a mixture of isopropyl alcohol and water, and a mixture of acetone and water for 30 days, the crystalline form can be kept unchanged in all of them.

[0165] 1.3 Competition experiment of crystalline form I and crystalline form IV of the compound as represented by formula A in solvent at room temperature About 15 mg of the crystalline form I of the compound as represented by formula A and 15 mg of the crystalline form IV of the compound as represented by formula A were mixed in 1 mL of solvent, ultrasonically dispersed to form a slurry, and suspended and equilibrated at room temperature, ensuring that there was always an excess of solid in the bottle during this period, and after 7 days, the solid was collected by centrifugation, the solvent was evaporated at room temperature, and XRPD was tested.

[0166] Conclusion: In the present invention, the crystalline form I and the crystalline form IV were all converted to the crystalline form I after competing in each solvent for 7 days at room temperature, and the stability of the crystalline form I was proved to be superior to that of the crystalline form IV. The solvents are methanol, ethanol, isopropyl alcohol, n-butanol, acetone, 2-butanone, methyl isobutyl ketone, dichloromethane, 2-methyltetrahydrofuran, acetonitrile, n-heptane, n-hexane, cyclohexane, cyclopentane, n-pentane, isopropyl ether, methyl tert-butyl ether, ethyl acetate, or isopropyl acetate.

[0167] 2. Stability of crystalline form I of the compound of formula A under high temperature, high humidity and light conditions The crystalline form I of compound as shown in formula A prepared in Example 11 is sampled and subjected to stability test on the influence factors of high temperature, high humidity and light irradiation. The test parameters include total impurity, moisture, content and crystalline form determination. The specific experimental process is as follows:

[0168] An appropriate amount of the crystalline form I sample of the compound represented by formula A was spread evenly on a clean glass dish and left open under conditions of high temperature (60±2°C), high humidity (25°C, RH92.5±5%) and light exposure (4500±500 Lux, 25°C). Sampling was performed on the 5th and 10th days, and the results are shown in Tables 7 to 9 below.

[0169] [Table 7]

[0170] [Table 8]

[0171] [Table 9]

[0172] remarks: Content measurement method: High performance liquid chromatography (Chinese Pharmacopoeia 2020 edition) <0512> According to the second method, the chromatography conditions are as follows. Octadecylsilane-bonded silica gel (SunFire C18, 3.5 μm, 4.6 × 150 mm) was used as the packing material, 0.05% trifluoroacetic acid in water was used as the mobile phase A, and 0.05% trifluoroacetic acid in acetonitrile was used as the mobile phase B. Isocratic elution was performed with A:B = 77:23. The flow rate was 1.0 mL / min, the detection wavelength was 230 nm, and the column temperature was 30 ° C. The test and control products were each adjusted to 0.1 mg / mL using methanol: 0.05% trifluoroacetic acid in water = 40:60 (volume ratio) as a diluent, and 10 μL of each was accurately measured and injected into the liquid chromatograph, and the chromatogram was recorded. According to the external standard method, the compound represented by formula A in the test product is 98.0% to 102.0% based on the anhydrous content, calculated by peak area.

[0173] Conclusion: From the data in Tables 7 to 9 above, it is clear that when the crystalline form I is left under the conditions of high temperature (60±2°C), high humidity (25°C, RH92.5±5%) and light irradiation (4500±500 Lux, 25°C) for 10 days, there is no significant change in each test index compared to before the test treatment for the influencing factors, and the stability of the crystalline form I is also good.

[0174] 3. Stability of Crystal Form I of Compound of Formula A under Accelerated Conditions The compound of formula A prepared in Example 11 is sampled for crystalline form I, and stability test is carried out under accelerated conditions. The test parameters include total impurities, moisture, content and crystalline form. The specific experimental process is as follows:

[0175] Form I samples of the compound of formula A were sealed in low density polyethylene pharmaceutical bags, sealed in polyester / aluminum / polyethylene pharmaceutical composite bags, and stored under accelerated stability conditions (40±2°C, RH75±5%). Samples were taken and tested at 1, 2, 3, and 6 months. The results are shown in Table 10 below.

[0176] [Table 10]

[0177] Conclusion: From the data in Table 10 above, it is clear that when the crystalline form I is stored under accelerated stability conditions (40±2°C, relative humidity 75±5%) for 6 months, each test index did not change significantly compared to before the accelerated test, and the stability of the crystalline form I is good.

[0178] It should be noted that the examples and embodiments described in the present invention are used for illustrative purposes only, and various improvements or modifications made in light of these will be presented to those skilled in the art, and are within the spirit and scope of this application and the scope of the appended claims. All publications, patents, and patent applications cited in this invention are incorporated herein by reference and may be used for any purpose.

Claims

1. Crystalline form I of the compound as represented by formula A, characterized in that it has diffraction peaks at 8.3±0.2°, 12.8±0.2°, 13.4±0.2°, 17.5±0.2°, 17.9±0.2°, and 23.3±0.2° in terms of 2θ in an X-ray powder diffraction spectrum using Kα radiation of a Cu target. 【Chemistry 1】

2. In the powder X-ray diffraction spectrum diagram using Kα radiation of the Cu target, there are further diffraction peaks at 8.3±0.2°, 11.2±0.2°, 12.2±0.2°, 12.8±0.2°, 13.4±0.2°, 17.5±0.2°, 17.9±0.2°, 20.8±0.2°, 22.4±0.2°, and 23.3±0.2° expressed as 2θ; 2. The crystalline form I of the compound as defined by formula A according to claim 1, characterized in that the compound can have diffraction peaks at 12.8±0.2°, 13.4±0.2°, 17.1±0.2°, 17.5±0.2°, 17.9±0.2°, 20.8±0.2°, 21.5±0.2°, 22.4±0.2°, 23.3±0.2°, 24.0±0.2°, 25.4±0.2°, 29.4±0.2°, and 34.5+0.2°.

3. The crystalline form I of the compound represented by formula A has a powder X-ray diffraction spectrum represented by the relative intensities of 2θ angle, d spacing, and peak height using Kα radiation of a Cu target, and the data of the relative intensities of 2θ angle, d spacing, and peak height of the diffraction peak are also shown in Table 3. 【Table 3】 and / or the infrared absorption spectrum of the crystalline form I of the compound represented by formula A is 3090 cm -1 , 3061 cm -1 , 2965 cm -1 , 2924 cm -1 , 2868 cm -1 , 2222 cm -1 , 1697 cm -1 , 1605 cm -1 , 1578 cm -1 , 1549 cm -1 , 1499 cm -1 , 1474 cm -1 , 1420 cm -1 , 1396 cm -1 , 1296 cm -1 , 1246 cm -1 , 1188 cm -1 , 1051 cm -1 , and 920 cm -1 There is an absorption peak at and / or the compound of formula A has an endothermic peak with an onset temperature of 193±2° C. and a peak temperature of 195±2° C. in a differential scanning calorimetry chart of crystalline form I; and / or the thermogravimetric graph of crystalline form I of the compound as represented by formula A shows no volatile loss when heated to 190° C.; and / or the crystalline form I of compound as represented by formula A according to claim 1, characterized in that in the dynamic moisture sorption diagram of said crystalline form I of compound as represented by formula A, there is a weight increase of only about 0.01% in the weight range of 0 to 95% relative humidity.

4. The crystalline form I of the compound represented by formula A has a powder X-ray diffraction spectrum shown in FIG. 2 using Kα radiation of a Cu target; and / or the infrared absorption spectrum of the crystalline form I of the compound as represented by formula A is shown in FIG. and / or the differential scanning calorimetry chart of the crystalline form I of the compound of formula A is shown in FIG. and / or the thermogravimetric graph of crystalline form I of the compound as represented by formula A is shown in FIG. and / or the crystalline form I of the compound as represented by formula A according to claim 3, characterized in that the dynamic moisture sorption diagram of said crystalline form I of the compound as represented by formula A is shown in Figure 6.

5. Method 1, which comprises cooling a mixture of a compound represented by formula A, THF, and a poor solvent at 60°C to 75°C to precipitate the compound, and filtering the mixture, wherein the poor solvent is methanol and / or water; or The method for preparing crystalline form I of compound as defined by formula A according to any one of claims 1 to 4, characterized in that the method 2 comprises cooling a solution of crystalline form III and / or VI of compound as defined by formula A and a mixed solvent of THF and isopropyl alcohol at 60°C to 70°C, precipitating a solid, and filtering the solid.

6. The compound represented by formula A can be prepared by referring to patent CN106008340A, and / or in method 1, the volume / mass ratio of THF to the compound as represented by formula A is 3.0 mL / g to 30.0 mL / g; and / or in method 1, the mixture is obtained by adding the compound as represented by formula A to a mixed solvent of THF and a poor solvent, or by dissolving the compound as represented by formula A in THF and then adding the poor solvent dropwise; and / or in method 1, the volume ratio of THF to the poor solvent is 0.5:1 to 5:1; And / or in method 1, the cooling temperature is -20°C to 20°C; And / or in method 1, the cooling rate is 5°C / h to 30°C / h; And / or in method 1, the filtration is reduced pressure suction filtration; And / or, in method 1, further comprising a drying operation after the filtration; And / or in method 2, the temperature is reduced to -20°C to 20°C; And / or in method 2, the cooling rate is 5°C / h to 30°C / h; And / or in method 2, the filtration is a vacuum suction filtration; And / or in method 2, further comprising a drying operation after the filtration; and / or in method 2, the volume ratio of THF to isopropyl alcohol in the mixed solvent is 0.5:1 to 2:1; and / or in method 2, the crystalline form III of the compound of formula A is obtained by a preparation method comprising removing a solvent from a solution of the compound of formula A in tetrahydrofuran; and / or in method 2, the crystalline form III of the compound as represented by formula A has diffraction peaks at 6.7±0.2°, 13.6±0.2°, 14.5±0.2°, 15.3±0.2°, 15.8±0.2°, 16.1±0.2°, 16.8±0.2°, 17.1±0.2°, 19.0±0.2°, 19.6±0.2°, 20.3±0.2°, and 22.6±0.2° in terms of 2θ in a powder X-ray diffraction spectrum using Kα radiation from a Cu target; and / or in method 2, the crystalline form VI of the compound of formula A is obtained by a preparation method including the steps of cooling a solution formed of the compound of formula A and 1,4-dioxane to −10° C. to −20° C., filtering and drying; and / or in scheme 2, the method for preparing crystalline form I of compound as represented by formula A according to claim 5, characterized in that crystalline form VI of compound as represented by formula A has diffraction peaks at 6.3±0.2°, 12.7±0.2°, 14.1±0.2°, 14.6±0.2°, 17.3±0.2°, 17.8±0.2°, 19.1±0.2°, 19.5+0.2°, 22.4±0.2°, 24.6±0.2° and 25.2±0.2° 2θ in powder X-ray diffraction spectrum using Kα radiation of Cu target.

7. In method 1, when the poor solvent is methanol, the volume ratio of the THF to the poor solvent is 0.5:1 to 2:1; and / or in method 1, when the poor solvent is water, the volume ratio of THF to the poor solvent is 0.5:1 to 5:1; And / or, in method 1, the cooling step further comprises mixing the mixture with isopropyl alcohol and cooling; And / or, in method 1, the drying is performed under reduced pressure at 65° C., and the drying time is 1 hour to 3 days; and / or Scheme 2, in the preparation of crystalline Form III of the compound of formula A, the removal of the solvent is carried out by distillation; and / or Scheme 2, the method for preparing crystalline Form III of compound of formula A further comprises filtering the solution of compound of formula A in tetrahydrofuran before removing the solvent; and / or in method 2, the crystalline form III of the compound of formula A has a powder X-ray diffraction spectrum of 2θ angle, d spacing and relative intensity of peak height using Kα radiation of Cu target, and the data of 2θ angle, d spacing and relative intensity of peak height of diffraction peak are as shown in Table 4, 【Table 4】 and / or in method 2, in the preparation of crystalline form VI of the compound of formula A, the temperature of the solution formed by the compound of formula A and 1,4-dioxane is 40°C to 120°C; and / or Scheme 2, in the preparation of crystalline form VI of compound of formula A, the cooling is rapid cooling; and / or Scheme 2, in the preparation method of crystalline form VI of compound of formula A, the filtration is vacuum suction filtration; and / or Scheme 2, in the preparation method of crystalline form VI of compound of formula A, the drying is vacuum drying; and / or in method 2, the preparation method of crystalline form I of compound as represented by formula A as claimed in claim 6, characterized in that in powder X-ray diffraction spectrum of crystalline form VI of compound as represented by formula A using Kα radiation of Cu target, the data of 2θ angle, d spacing and relative intensity of peak height of its diffraction peak are as shown in Table 5. 【Table 5】

8. The crystalline form III of the compound represented by formula A has a powder X-ray diffraction spectrum shown in FIG. 8 using Kα radiation of a Cu target; and / or the DSC chart of the crystalline form III of the compound of formula A is as shown in FIG. and / or the TGA chart of the crystalline form III of the compound represented by formula A is as shown in FIG. 10; and / or the crystalline form VI of the compound as represented by formula A has a powder X-ray diffraction spectrum as shown in FIG. 12 using Kα radiation of a Cu target; and / or the DSC chart of the crystalline form VI of the compound of formula A is as shown in FIG. 13 ; and / or the TGA chart of the crystalline form VI of the compound of formula A is as shown in FIG.

14.

9. Use of crystalline form I of the compound as defined by formula A according to any one of claims 1 to 4 in the manufacture of a medicament for preventing and / or treating hyperuricemia or diseases related thereto, comprising The disease associated with hyperuricemia is, for example, one or more of gout, hypertension, diabetes, hypertriglyceridemia, metabolic syndrome, coronary heart disease, and kidney damage.

10. Use of crystalline form I of compound as defined by formula A according to any one of claims 1 to 4 in the manufacture of a urate transporter 1 inhibitor, said urate transporter 1 inhibitor being capable of being used in vivo in a mammal or in vitro, primarily for experimental purposes.

11. A pharmaceutical composition comprising a therapeutically effective amount of crystalline Form I of the compound as defined by formula A according to any one of claims 1 to 4, and one or more pharma- ceutically acceptable carriers and / or diluents.

12. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form I of the compound as defined by formula A of any one of claims 1 to 4 and another uric acid lowering drug, said other uric acid lowering drug can be one or more of a urate transporter 1 inhibitor, a xanthine oxidase inhibitor, a xanthine oxidoreductase, and a xanthine dehydrogenase inhibitor.

Citation Information

Patent Citations

  • Condensed Ring Derivatives, Method for Producing the Same, Intermediates, Pharmaceutical Compositions, and Applications

    JP2018509451A